What is Klaron used for?

Klaron is indicated for Acne vulgaris, Amebic infection, Blepharoconjunctivitis, Chlamydial conjunctivitis, Gardnerella Vaginalis Bacterial Vaginosis.

Klaron is developed by Merck & Co..

What development phase is Klaron in?

Klaron is FDA-approved (marketed).

What are the side effects of Klaron?

Common side effects include Stevens-Johnson syndrome, Local hypersensitivity, Syndrome resembling systemic lupus erythematosus.

What is the generic name of Klaron?

SULFACETAMIDE is the generic (nonproprietary) name of Klaron.

Last reviewed 2026-05-13 · How we verify

Klaron (SULFACETAMIDE)

Merck & Co. · FDA-approved approved Small molecule Quality 55/100

Klaron (SULFACETAMIDE) is a sulfonamide antibacterial small molecule drug originally developed by ORTHO MCNEIL PHARM and currently owned by Schering. It targets dihydrofolate reductase and has been FDA-approved since 1945 for various indications including acne vulgaris, amebic infection, and blepharoconjunctivitis. Klaron is off-patent with 15 generic manufacturers available. Key safety considerations include its antibacterial properties which may contribute to antibiotic resistance. As a sulfonamide, it may also cause hypersensitivity reactions in some individuals.

At a glance

Generic name	SULFACETAMIDE
Sponsor	Merck & Co.
Drug class	Sulfonamide Antibacterial
Target	Dihydrofolate reductase
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved
First approval	1945

Approved indications

Acne vulgaris
Amebic infection
Blepharoconjunctivitis
Chlamydial conjunctivitis
Gardnerella Vaginalis Bacterial Vaginosis
Infective blepharitis
Iridocyclitis
Pityriasis simplex
Seborrheic dermatitis
Superficial Ocular Infection
Trachoma
Uveitis
Vulvovaginitis

Common side effects

Stevens-Johnson syndrome
Local hypersensitivity
Syndrome resembling systemic lupus erythematosus

Key clinical trials

Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Intraductal Meibomian Gland Probing Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Klaron CI brief — competitive landscape report
Klaron updates RSS · CI watch RSS
Merck & Co. portfolio CI